Open Orphan considers spinning out assets Updated / Tuesday, 13 Apr 2021 18:30 Business Editor Specialist pharmaceutical services clinical research company, Open Orphan, is considering a possible spin-out of certain non-core development intellectual property assets. The company said the potential demerger is at an advanced stage of planning. The assets include HVO-001, a candidate drug with potential applications in the treatment of respiratory disease. However, the assets do not include the company's equity interests in Imutex Limited and PrEP Biopharm Limited. "Over the last year we have been busy transforming Open Orphan into a profitable enterprise with a world leading position testing vaccines and antivirals using human challenge studies," said Cathal Friel, Executive Chairman of Open Orphan.